Document is current

Article History

Received: 5 September 2020

Accepted: 6 December 2020

First Online: 4 January 2021

Compliance with ethical standards

:

: U.E. is an employee of Roche. O.H. has received research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals, Fujirebio, and Euroimmun. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Lilly, Roche, and Fujirebio. B.L.M. serves as Medical Director for the John Douglas French Foundation; Scientific Director for the Tau Consortium; Director/Medical Advisory Board of the Larry L. Hillblom Foundation; Scientific Advisory Board Member for the National Institute for Health Research Cambridge Biomedical Research Centre and its subunit, the Biomedical Research Unit in Dementia (UK); and Board Member for the American Brain Foundation. W.J. has served as a consultant to Genentech, Biogen, Bioclinica, CuraSen, and Grifols. G.D.R. receives research support from Avid Radiopharmaceuticals, GE Healthcare, and Life Molecular Imaging and has received consulting fees or speaking honoraria from Axon Neurosciences, Roche, Eisai, and Genentech. All other authors have no relevant financial or non-financial interests to disclose.

: This study was performed in line with the principles of the Declaration of Helsinki. The study was approved by the University of California (San Francisco and Berkeley), Lawrence Berkeley National Laboratory (LBNL), and the Ethical Committee of Lund University, Sweden, institutional review boards for human research. Each ADNI study site received approval from its institutional ethical standards committee on human experimentation.

: Written informed consent was obtained from all participants or their surrogates.